|
BioScreening - organic compounds for screening
Clinical Trials NewsGTCbio’s 3rd Imaging in Pre-clinical & Clinical Drug Development Conference. March 17-18, 2008 - San Diego, CA - The obstacles to successful drug discovery and development are numerous and well appreciated. In discovery, from target identification through lead optimization and validation, and in development, from first-in-man studies through large registration trials, inefficiencies and uncertainties complicate even well-funded efforts by sophisticated and industrious scientists and clinicians. Despite huge outlays by the worldwide pharmaceutical research [...]
Biological Drugs Spurring an Evolution in Injectable Drug Delivery - (Amherst, NH) - The success of recombinant protein drugs such as Enbrel, Remicade, and Herceptin in treating refractory conditions is fueling the search for protein and peptide-based therapeutic agents in oncology, inflammation and a host of other disease classes. Led by the proliferation of antibody-based drug candidates, biological drugs as a class continue to outpace [...]
Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity - Patients with FDA-defined Valvulopathy Permitted to Enroll in 2nd and 3rd Pivotal Trials - Echocardiogram Screening Requirement Eliminated
SAN DIEGO, Dec. 13 /PRNewswire-FirstCall/ — Arena Pharmaceuticals, Inc. today announced the initiation of patient screening in the second and third Phase 3 pivotal trials evaluating the efficacy and safety of its lead drug candidate, lorcaserin hydrochloride, for [...]
7th Annual Protein Kinases Congress 10-12 March 2008 in Crowne Plaza Berlin City Centre, Berlin, Germany - Innovating kinase inhibitor development is the key to successful clinical development. At Informa Life Sciences 7th Annual Protein Kinases Congress hear the latest thinking and strategies towards creating a selective inhibitor. Learn about new targets, industry trends in structure-based drug design, clinical case-studies and discuss the issue of cardiotoxicity.
For more information visit: http://www.iir-events.com/IIR-Conf/page.aspx?id=9547
New Clinical Trial Code break System ‘Safecode’ - ‘Safecode’ is a new system for clinical trials represents a significant enhancement over traditional CODEBREAK product identification
methods.
Our system allows confidential information to be printed using industry standard inkjet technology.
The printed information is illegible unless a tamper evident strip is removed. This ensures that any effort to compromise the security of data is immediately apparent.
http://www.acs-labels.co.uk/Safecode.htm
BIOSERVE and DNAPRINT(R) GENOMICS FORM STRATEGIC ALLIANCE TO PROVIDE CLINICAL PATIENT SAMPLES TAGGED WITH GENETIC ANCESTRY DATA - BioServe’s fully annotated clinical samples across many diseases to be tagged with ancestry information using DNAPrint’s genetic ancestry tests
BELTSVILLE, MD., Oct. 9, 2007 – BioServe today announced the formation of strategic alliance with DNAPrint® Genomics, Inc. (OTCBB: DNAG) to provide biomedical researchers with clinical DNA samples that for the first time will include genetic ancestry [...]
New compounds promising candidates for neurodegenerative disease drug development - Scientists have developed a novel strategy for tackling neurodegenerative diseases such as Huntington’s disease: encouraging an individual’s own cells to “eat” the malformed proteins that lead to the disease.
Huntington’s disease is one of a number of degenerative diseases marked by clumps of malformed protein in brain cells. Symptoms include abnormal movements, psychiatric disturbances like depression [...]
Oxford International’s Clinical Trial Management Congress 6th-7th November 2006 Philadelphia, USA - Oxford International are pleased to announce the Clinical Trial Management Congress, to be held in Park Hyatt Hotel at the Bellevue, Philadelphia, USA on 6th – 7th November 2006.
The congress offers attendees an unprecedented opportunity to network with leading senior-level clinical trials and technology executives, to identify successful strategies in maximising clinical trial productivity, through [...]
GENFIT initiates Phase II clinical trials with GFT14 - Phase I results revealed very good tolerance in healthy volunteers as well as an
excellent security profile for GFT14, one of the medical candidates that GENFIT is
developing to tackle cardiometabolic risk.
Lille (France), Cambridge (Massachusetts), 2nd May 2006 – GENFIT, the
biopharmaceutical company engaged in the discovery and development of medical
candidates in the areas of cardiovascular, inflammatory and [...]
Links
|
|
